Posted by Ivan Fernández Vega, MD PhD on 25 January 2019
It is estimated that around 45 million people in the world suffer from dementia, most of them over 60 years old. With increases in life expectancy, this incidence is projected to double every 20 years .
Last comment on 31 January 2019 by Soraya Valles, PhD
In the last few years, we have witnessed a tremendous advancement in cell culturing methods. The scene has been dominated by the optimization of 3D in vitro models either in the form of dissociated neuronal cultures or of the so-called organoids.
Last comment on 5 January 2019 by Doo Yeon Kim, Ph.D.
Alzheimer's disease (AD) is the most prevalent form of dementia with large impact on population over the age of 65 years . The most distinctive symptomatic phase during the disease is the decline of the cognition with the loss of synapses [2-5].
Last comment on 26 December 2018 by Claudio Russo, PhD
Posted by Amy Clements-Cortes, PhD on 16 November 2018
This blog is a follow-up to the one I published in August 2017, titled “Music Experiences for Persons with AD”. In this piece, I am focusing on one of the experiences: Music Therapy. As an inexpensive, evidence-based, and non-pharmacological treatment, music therapy should highly be considered in the total care package for persons living with AD.
Last comment on 16 November 2018 by Michael Gordon, MD MSc
Posted by Stefano Sensi, MD PhD on 2 November 2018
In Alzheimer’s disease (AD), we are gaining great ground in the field of early diagnosis, but disease-modifying drugs are still missing. While many studies have been focused on the pathogenic role of amyloid-β (Aβ) dysmetabolism, recent preclinical and clinical findings revealed a more complex picture. In AD, we need to embrace a complex view of the disease state as a condition resulting from the converging failure of health-controlling systems and networks; A condition shaped by the combination of our “omic” blueprint and the influence of the environment.
Last comment on 11 November 2018 by Paula Moreira, PhD
The search to find therapeutic targets in Alzheimer's disease (AD) has been dominated for over 25 years by research into the roles in the initiation and progression of dementia of the amyloid beta protein (Aβ) [1, 2], derived from the β-pathway of amyloid beta protein (AβPP) cleavage.
An ancient Indian subcontinent parable tells a story in which a group of blind men each touch a different part of an elephant. They cannot agree on the nature of the elephant because none of them observed the elephant as a whole.
Posted by Lawrence Broxmeyer, MD on 3 November 2017
Alois Alzheimer might have mentioned plaques and tangles in a single short paper on pre-senile dementia in 1907, but it was the co-discover of Alzheimer’s disease (AD), Oskar Fischer, who in that same year far more extensively reported neuritic plaque in 12 cases of senile dementia, a condition which he and many others refused to differentiate from Alzheimer’s “pre-senile” dementia.
Last comment on 17 March 2019 by Lawrence Broxmeyer, MD
Dr. Lawrence Broxmeyer MD1* and Dr. George Perry PhD2
1 Chief Scientist of the New York Institute of Medical Research, USA
2 Professor and Chief Scientist of the Brain Health Consortium. Semmes Foundation Distinguished University Chair in Neurobiology, the University of Texas at San Antonio (UTSA)
As in the case of other CNS infectious agents claimed to cause Alzheimer’s disease [AD], the theory that Herpes Simplex Virus or any other herpes virus causes AD is still controversial. In their 2013 review, Mawanda and Wallace’s Can Infections Cause Alzheimer’s Disease 1 gave seven annotated references as to why HSV-1 “remains questionable” as a cause for Alzheimer’s. Some say that Herpes simplex virus type 1 in conjunction with APOE-epsilon 4 allele is a strong risk factor for AD, though either of these features alone do not increase the risk for AD. It is claimed that people who have symptoms of late onset Alzheimer’s disease (AD) and have one or more APOE-ε4 gene copies are more likely to have AD. However, APOE- ε 4 is not diagnostic of AD and should not be used to screen people or their family members. Furthermore, many of those who have e4 alleles will never develop AD. And even in symptomatic people, only about 60% of those with late onset AD will have APOE- ε 4 alleles.2,3 Not only is the APOE gene not a clinical diagnosis, but just as importantly, “negative” results do not confer later protection. Beyond APOE, there are at least 20 other genetic factors which have been shown to have a small but significant role in determining Alzheimer risk.4 And true understanding of genetic test results also requires attention to potential inaccurate results. For example, APOE-ε4 alleles themselves are known to show a distinct increase in tuberculosis.5 Before widespread institution of anti-herpetics is unleashed on the general population, this is an area which requires further research.
Citation: Lawrence Broxmeyer and George Perry. “Alzheimer’s Disease: Questions Raised by a Herpes Virus Origin”. Current Opinions in Neurological Science 3:2 (2019): 652-660. DOI: 10.5281/zenodo.2592845.
Posted by Amy Clements-Cortes, PhD on 25 August 2017
Music is a wonderful, non-pharmacological intervention to be considered for persons with Alzheimer’s disease (AD). In order to provide appropriate and beneficial music interventions for persons with AD, it is important to understand the range of music experiences that may offer effective complementary management of symptoms associated with AD.
Posted by Judith Miklossy, MD, PhD, DSc on 27 February 2017
The World Health Organization  has declared dementia as public health priority. Alzheimer’s disease (AD) is the most frequent cause of dementia. The challenges to governments to respond to the growing number of people with dementia are substantial. Tremendous efforts have been made in research during the last four decades highlighting important aspects of the pathogenesis of AD, but if the cause of AD is not defined, and treatments to prevent the disease are not provided, the world will face an unprecedented health-care problem by the middle of the century.
Last comment on 23 May 2017 by Lawrence Broxmeyer, MD
Posted by Jack de la Torre, MD, PhD on 10 February 2017
There is increasing concern not only in Alzheimer’s disease (AD) research, but all of modern investigations, that false findings may be the majority or even the vast majority of published research claims .
Last comment on 15 April 2017 by Markku Kurkinen, PhD
Alzheimer’s disease (AD) is the most common cause of dementia and remains incurable. Its prevalence is rising, current afflicting 5 million Americans with projections to affect millions more as the population ages .
Posted by Sergio Salmerón, MD PhD on 2 December 2016
Among patients diagnosed with Alzheimer's disease (AD), the percentage in the severe stage ranges from 28%  to 33%  to a maximum of 50% . In institutionalized patients, prevalence is higher, with an estimated 75% of patients with severe AD .
Last comment on 2 December 2016 by Maheen Adamson, PhD
Posted by Martha Clare Morris, Sc.D. on 9 September 2016
There is no doubt that nutrition is involved in brain health and the development of neurodegenerative diseases. This is an important area of research in the dementia field that has suffered from the absence of trained experts in nutrition and nutritional epidemiology.
Last comment on 30 September 2016 by Thomas B. Shea, PhD
Posted by Ruth Itzhaki, MSc PhD MA on 19 August 2016
Most of us harbour in our body several types of herpes virus—perhaps as many as five—and we provide them with a safe and secluded haven for life, as there are no methods for eliminating or expelling them.
Last comment on 19 August 2016 by Brian Balin, PhD
Posted by Giulio Pasinetti, MD, PhD on 5 August 2016
The ability to maintain normal psychological and physical functioning and avoid serious mental illness when exposed to stress and trauma, a phenomenon known as resilience, is a topic that has been investigated over the past several years with increasing attention [1,2].
Last comment on 5 August 2016 by Heather Snyder, Ph.D.
Posted by Pierre Krolak-Salmon, MD PhD on 29 April 2016
As disease-modifying drugs are crucially missing from the pipeline of treatments available for people with Alzheimer’s disease (AD) or related disorders, physicians, scientists, and public health experts are promoting the concept of early diagnosis.
Last comment on 29 April 2016 by Philip Scheltens, Prof.dr
Alzheimer’s disease (AD) transgenic mice have been used as a standard model for AD drug discovery and basic mechanistic studies. These mouse models overexpress amyloid β precursor protein (APP) or APP/presenilin (PS) with single or multiple familial AD (FAD) mutations, which lead to excess accumulation of amyloid β (Aβ), a well-known driver for AD pathogenesis.
Last comment on 8 April 2016 by Christopher Navara
The microtubule-associated protein tau is mainly expressed within neurons where it performs its physiological function of microtubule stability. However, extracellular tau is found in models of tau overexpression in which neuronal degeneration and cell death is prominent.
Last comment on 8 January 2016 by Alejandra Alonso, PhD
Posted by Jack de la Torre, MD, PhD on 30 October 2015
The field of Alzheimer research has reached an impasse after more than 100,000 clinical and scientific papers published in the last 40 years, because there is yet no hope, no effective treatment, and no knowledge of what causes this dementia.
Last comment on 24 November 2015 by Gustavo Román, MD, DrHC
For most people, older adulthood is associated with some decline in memory and in some aspects of cognitive function. These are age-related changes  that are widely expected, understood, and accepted by the general public.
Last comment on 16 October 2015 by Amy Jenkins, MSc MSc PhD
Posted by Allyson Rosen, PhD, ABPP-CN on 13 August 2015
Over the past few years there has been tremendous progress in diagnosis and therapeutic trials on Alzheimer’s disease (AD) and related dementias. Overall, the cost/benefit relationship is shifting with success.
Last comment on 21 October 2016 by Allyson Rosen, PhD, ABPP-CN
Depression in Alzheimer’s disease (AD) has a substantial impact on disability, disease progression, and caregiver burden. Furthermore, depressive symptoms in normal aging, as well as in mild cognitive impairment (MCI), are associated with cognitive and functional decline.
Two hundred issues and nearly twenty years have positioned JAD at the center of printed and electronic peer-reviewed publications in Alzheimer's disease, as a venue that reflects the breadth of research in the field worldwide.
Last comment on 28 March 2017 by Lawrence Broxmeyer, MD